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Background: The aim of this human investigation is to ex-
plore the relationship of gingivitis with salivary biomarkers,
periodontal pathogens, and interleukin (IL)-1 polymorphism
after a transient inflammatory burden.
Methods: Thirty healthy human participants were random-
ized by IL-1 genotype status to control for potential influences
of this particular single nucleotide polymorphism on the in-
flammatory profile. Oral hygiene practices ceased for 21
days to induce gingivitis (induction), after which home care
was reinstated until 35 days (resolution). Clinical parameters
included plaque (PI) and gingival (GI) indices and papillary
bleeding score (PBS). Levels and proportions of 40 subgingi-
val bacteria were determined using checkerboard DNA-DNA
hybridization. Saliva was analyzed using a multiplex protein
array for 30 biomarkers associated with host defense, inflam-
mation, tissue destruction, and angiogenesis.
Results: Mean PI, GI, and PBS values were significantly in-
creased during induction and decreased during resolution as
measured at 35 days (P <0.01), although no differences
were observed between IL-1 groups. Participants were strati-
fied as either ‘‘high’’ or ‘‘low’’ responders based on inflamma-
tory response (high: GI >1.5; low: GI £1.5). Baseline levels of
salivary IL-6 and IL-8 demonstrated the highest ability to dis-
criminate between high and low responders (area under the
curve [AUC] of 0.81 and 0.72, respectively). Salivary bio-
markers, matrix metalloproteinases (MMPs), and bacterial
biofilm were combined to generate receiver operating charac-
teristic curves. High levels of IL-6 and MMP-1 at baseline dem-
onstrated the strongest ability to predict high responders
(AUC of 0.89; odds ratio of 17.0; 95% confidence interval,
1.7 to 171.7).
Conclusion: In this proof-of-concept investigation, we iden-
tified specific biomarker and microbial signatures that are
associated with gingival inflammation (ClinicalTrials.gov num-
ber NCT00980525). J Periodontol 2012;83:79-89.
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G
ingivitis is a local inflammatory
response to an oral infection in-
volving an average of three to
four teeth that affects 50% of the adult
population.1 Although dental plaque
biofilm is the primary etiology of most
periodontal diseases, patients are not
equally susceptible and do not respond
similarly to professional care.2 Multiple
genetic and environmental risk factors
predispose an individual to periodonti-
tis,3,4 but the influence of these factors
on gingivitis is uncertain.
Although periodontal diseases are
initiated by bacterial pathogens, it is the
activation and mediation of host inflam-
matory responses that are ultimately
responsible for the destructive events oc-
curring in the periodontium.5 Studies of
the host immune response to pathogenic
bacteria have contributed to the current
understanding of the pathogenesis of
periodontal diseases.6,7
The experimental gingivitis model is
widely used to study the gingival events
andmicrobiology thatoccurduringabac-
terially induced transition from a state of
health to inflammation because it pro-
vides a well-controlled environment
to study the pathogenesis and treatment
of gingivitis.8 Limitations of the expe-
rimental gingivitis model include inter-
examiner differences when measuring
plaque (PI) and gingival (GI) indices and
the 10- to 21-day requirement for gingivi-
tis to be clinically measured.8
Studies examining levels of proinflam-
matory and regulatory biomarkers in
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gingival crevicular fluid (GCF) and whole saliva of var-
ious disease states have provided insight to the diag-
nostic and prognostic value of these oral fluids.9-13
Putative biomarkers, such as cytokines and matrix
metalloproteinases (MMPs), found in whole saliva,
have been shown to correlate with actively progress-
ing periodontal diseases.11 In fact, identification of se-
lect biomarkers combined with specific periodontal
pathogens provides an even more accurate assess-
ment and prediction of periodontal diseases than tra-
ditional clinical indices.14 Furthermore, when active
sites in periodontally susceptible patients are recog-
nized earlier, oral health care costs can be reduced.10
Although gingival fluid biomarker associations with
experimental gingivitis have been reported,3 little is
known about how the combination of a patient’s levels
of salivary biomarkers and presence of oral microor-
ganisms might predict susceptibility to gingivitis. This
study, therefore, seeks to determine whether salivary
biomarkers and other biologic parameters at baseline
might be predictive of ‘‘high’’ versus ‘‘low’’ responders
to the bacterial challenge in the experimental gingivitis
model, thereby allowing more objective determination
of the gingival response and shorter runs of the model.
Such information should be of high value in the search
for technologies to control or prevent gingivitis.
MATERIAL AND METHODS
Study Population
Participants provided written informed consent to the
protocol approved by the University ofMichigan Health
Sciences Institutional Review Board before administra-
tion of research-related procedures. The investigation
was registered through National Institutes of Health
ClinicalTrials.gov (identifier no. NCT00980525) and
was conducted at the Michigan Center for Oral Health
Research.
Because genetic differences influence monocyte ex-
pression and gingival fluid levels of interleukin (IL)-
1b,7,15 we compared experimental gingivitis responses
in 15 participants who were IL-1 genotype positive and
15 participants who were IL-1 genotype negative. Par-
ticipants were volunteers recruited from February
2009 to February 2010 and re-
ceived monetary compensation
for their participation.
White participants aged 18 to
40 years with ‡20 permanent
teeth were considered candi-
dates. Inclusion criteria consisted
of: 1) periodontal probing depth
(PD) £4 mm at six sites per tooth
on all teeth; 2) mean clinical at-
tachment level (CAL) £2 mm on
all teeth and mean PI,16 GI,17
and papillary bleeding score18
(PBS)£1atthescreeningandconfirmationappointment;
and 3) compliance with all study requirements.
Participants were excluded if they: 1) were current
smokers, quit smoking <1 year, or had a pack-year
history ‡10 (pack years was calculated by multiplying
the number of years smoked by the average number
of cigarette packs smoked per day); 2) had cotinine
level ‡200 ng/mL; 3) had antibiotic therapy within 3
months of baseline or need of prophylactic antibiotic;
4) had chronic consumption of medications known to
affect the periodontal status; 5) were new oral contra-
ceptives users within 3 months of baseline, or users
who were planning on starting oral contraceptives
or use of contraceptive injection# during the study;
6) were pregnant or lactating; 7) had current ortho-
dontic or periodontal treatments; 8) had history of
alcoholism or drug abuse; 9) had untreated carious
lesions or defective restorations that could exacerbate
during oral hygiene abstinence; or 10) had diseases of
the immune system, or any medical condition that
may influence the outcome.
Clinical Procedures
The timeline shown in Figure 1 summarizes the details
of each appointment. Three weeks before baseline
(i.e., screening), qualifying participants (n = 61) re-
ceived a complete periodontal examination, prophy-
laxis, oral hygiene instructions, and topical fluoride
application. Full-mouth PI,16 GI,17 PD, and CAL were
recorded using a periodontal probe.** PBS18 was
measured using a triangular-shaped toothpick.†† Par-
ticipants provided a urine specimen to confirm their
non-smoking status via cotinine levels <200 ng/mL.
All participants refrained from using anti-inflamma-
tory toothpaste between screening and confirmation
visits.
Seventeen days after the initial visit (i.e., confirma-
tion appointment; day -4), compliance was reas-
sessed by measure of full-mouth PI, GI, and PBS to
Figure 1.
Timeline of the experimental gingivitis study. Genotype-periodontal susceptibility test; prophy-
prophylaxis; bacteria-subgingival plaque collection.
# Depo-Provera, Pharmacia & Upjohn Company, Division of Pfizer, New
York, NY.
** University of North Carolina Dental Probe, PCP-UNC 15, Hu-Friedy,
Chicago, IL.
†† Stim-U-Dent, Johnson & Johnson, New Brunswick, NJ.
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ensure maximal gingival health. Participants with
mean PI, GI, or PBS >1 were excluded. During the in-
duction phase (i.e., day 0 to day 21), all measures of
oral hygiene were discontinued, and participants were
instructed to refrain from using mouth rinses or chew-
ing gums with anti-inflammatory properties. At day
21, a professional prophylaxis and topical fluoride
were provided. During the resolution phase (i.e.,
day 21 to day 35), oral hygiene procedures were rein-
stituted. Participants were reevaluated at day 35 to
ensure reestablishment of gingival health. Saliva, clin-
ical measurements, and bacterial plaque were col-
lected at days 0, 3, 7, 10, 14, 21, and 35. Clinical
measurements included PI and GI on four randomized
teeth and full-mouth PBS.
Three examiners (AL, JSK, and CBG) calibrated
on PD and CAL before the beginning of the study. Ex-
aminers demonstrated at least 96% of PD mea-
surements within 1 mm of each other with a 95%
confidence interval of (0.88, 0.99) and at least 93%
of CAL measurements within 1 mm of each other with
a 95% confidence interval of (0.84, 0.97). Examiners
completed training and calibration on PI, GI, and
PBS. Examiners and participants were masked to
IL-1 genotype results.
IL-1 Genotype Analysis
A genetic test was used to identify participants who had
specific variations in the IL1A and IL1B genes. Buccal
cells were obtained from participants by brushing their
cheek with a cytology brush.‡‡ Brushes were air dried
and mailed to a Clinical Laboratory Improvement
Amendments–certified laboratory§§ for DNA extrac-
tion and genotyping.
The polymorphic loci assessed were IL1A + 4845
(rs17561) and IL1B + 3954 (rs1143634). Single nu-
cleotide polymorphisms (SNPs) were genotyped by
polymerase chain reactions targeting the sequence
surrounding SNPs studied. Multiplexed single-base
extension reactions were performed, genotypes were
analyzed,ii and final machine-determined genotypes
were verified by a laboratory technologist masked
to all participant data. Patients with composite geno-
types that included (IL1A + 4845 = guanine/thymine
or thymine/thymine) and (IL1B + 3954 = cytosine/
thymine or thymine/thymine) were classified as ‘‘pos-
itive’’ for increased risk for more severe chronic peri-
odontitis.
Whole Saliva Collection and Analysis
Unstimulated whole saliva was collected from each
participant at the beginning of the appointment and
stored at -80C until analysis, as described previously
by Kinney et al.14
Inflammatory biomarker expression was quantified
using a custom human 30-plex protein array that was
optimized for sensitivity, specificity, stability, and
intraassay coefficient of variation by comparing
to single cytokine enzyme-linked immunosorbent
assays.¶¶ The 30-biomarker panel consisted of C-
reactive protein, Fcr RIIB/C, granulocyte colony stim-
ulating factor (GCSF), interferon-g (IFN-g), IL-1a,
IL-1b, IL-1ra, IL-1sRI, IL-2, IL-6, IL-8, IL-10, IL-12
(p40), IL-12 (p70), IL-17, interferon-induced protein-
10 (IP-10), monocyte chemoattractant protein-1
(MCP-1), macrophage inflammatory protein (MIP)-
1a, MIP-1b, MMP-1, MMP-2, MMP-8, MMP-9, MMP-
10, regulated on activation normal T-cell expressed
and secreted protein, serum amyloid A, stromal cell-
derived factor-1a, tissue inhibitor of MMP (TIMP)-1,
TIMP-2, and tumor necrosis factor-a.
After receipt, the array kits were stored at -20C.
Before each assay, whole saliva samples were thawed
at room temperature and microcentrifuged at 8000
to 10,000 · g for 5 minutes to obtain a cell-free super-
natant.
Each slide contained known concentration of stan-
dards (in picograms per milliliters) for each cytokine,
used for making serial dilutions to yield a six-point
standard curve, with sample diluent serving as the
negative control. Standards and experimental sam-
ples were incubated overnight at 4C, followed by
washing unbound materials. Detection antibody was
bound to antigens within each well. Cyanine 3 equiv-
alent dye-conjugated streptavidin was pipetted into
each well, which bound to the detection antibody
associated with immune complexes. Slides were incu-
bated, and fluorescence intensity was detected using
a laser scanner.## Resultant signals of samples were
compared to the standard curve for each of the 30
cytokines to determine concentrations of each cyto-
kine within the samples. Data were extracted and an-
alyzed using microarray analysis software.***
Subgingival Bacterial Isolation and Analysis
After collection of saliva and measurement of clinical
parameters, subgingival plaque was collected from
the mesio-buccal surface of four randomly selected
teeth. A randomization chart was created to ensure
that each site was sampled only once.
After removal of supragingival plaque, subgingi-
val plaque samples were collected using sterile
curets.††† Samples were placed into labeled vials
containing 150 mL of Tris-EDTA buffer (10 mM
Tris-HCl, 1 mM EDTA, and 500 mL distilled water
[pH 7.6]), after which 100 mL of 0.5 M NaOH was
‡‡ Part #25-2199, Puritan Medical Products, Guilford, ME.
§§ Interleukin Genetics, Waltham, MA.
ii CEQ8800 Instrument, Beckman Coulter, Brea, CA.
¶¶ Quantibody Custom Array, RayBiotech, Norcross, GA.
## Axon Gene Pix, RayBiotech.
*** RayBio Q Analyzer software, RayBiotech.
††† Gracey curets, Hu-Friedy.
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added to each vial. Samples were stored at 4C until
processed.
Detection of 40 bacterial species was evaluated by
checkerboard DNA-DNA hybridization technique.19
Samples were lysed, and DNA was pipetted on a nylon
membrane using a miniblotter apparatus.‡‡‡ After fix-
ation of DNA to the membrane, the membrane was
placed in another blotting apparatus,§§§ with lanes
perpendicular to the orientation of the DNA of the
samples. Digoxigenin-labeled whole chromosomal
DNA probes to 40 subgingival species were loaded
in individual lanes of the miniblotter. After hybridiza-
tion, membranes were washed at low and high strin-
gency. Hybrids were detected using anti-digoxigenin
antibody and conjugated with alkaline phosphatase,
followed by detection using a chemifluorescence sub-
strate.iii The intensity of fluorescence signals gener-
ated by the probe-target hybridization was read with
computer-linked fluorimager.¶¶¶ Each run contained
two lanes of standards with a concentration of 105
and 106 cells of each species. Sensitivity of the assay
and concentration of each DNA probe were adjusted
to allow detection of ‡104 cells of a given species.
Signals were compared to standards on the same
membrane to generate absolute
counts. The inability to detect
a signal was recorded as zero.
Statistical Analyses
Differences in demographic char-
acteristics and mean clinical
parameters between IL-1 geno-
type-positive and genotype-nega-
tive participants were assessed
using t tests for continuous mea-
sures and x2 tests of association
for categorical measures.
All microbiologic, salivary,
and clinical outcomes were
averaged within each partici-
pant before being analyzed.
For certain analyses, summary
measures for six subgingival
complexes described by Soc-
ransky et al.20 were obtained
by adding the mean values of
each member of a given com-
plex. Significance of changes
over time in proportions of mi-
crobial complexes was deter-
mined using the Friedman
test. Significance of differences
in microbial counts between
groups was tested using the
Mann-Whitney U test, whereas
significance of changes over
time in each group separately was sought using the
Friedman test.
Participants were stratified into high and low re-
sponders such that high responders were character-
ized by a mean GI >1.5 at any time point between day
3 and day 21. Low responders were defined as par-
ticipants with a mean GI £1.5 at all time points be-
tween day 3 and day 21. Levels of day 0 salivary
biomarkers and periodontal pathogens were ranked
by their area under the curve (AUC) of the receiver
operating characteristic (ROC) curve for discrimi-
nating between high and low responders. Bio-
markers that gave the highest AUCs were selected
in the hopes of generating a composite ROC curve
with higher AUC than each of its components.
Composite ROC curves were generated by combin-
ing the values of three biomarkers at baseline in a logis-
tic regression model predicting for progression of GI
>1.5. Each biomarker was classified individually as
being high in a participant if that participant’s value
was above the value that produced equal values of
Figure 2.
Patient flowchart illustrating participant recruitment and disposition.
‡‡‡ MiniSlot, Immunetics, Boston, MA.
§§§ Miniblotter 45, Immunetics.
iii AttoPhos, GE Healthcare, Arlington Heights, IL.
¶¶¶ Storm Fluorimager, GE Healthcare, Sunnyvale, CA.
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sensitivity and specificity. Odds ratios were used to de-
termine odds of progression of GI >1.5 in participants
high in all three biomarkers relative to participants
not high in all three biomarkers. Standard errors
(SEs) were computed using generalized estimating
equations to account for the correlation of values mea-
sured longitudinally on the same participant. All P
values were adjusted for multiple comparisons be-
tween IL-1 genotype-positive and genotype-negative
patients so as to reduce the rate of false-positive find-
ings.
RESULTS
A flowchart of participants in the study is provided
(Fig. 2). One hundred forty-three participants were
screened for eligibility. Eighty-two participants failed
the phone screen, and 28 did not meet study inclusion
criteria. Two participants withdrew because of their
inability to comply with abstinence of oral hygiene.
Minor transient adverse events were reported and in-
cluded soft and hard tissue sensitivity, altered taste
sensation, and traumatic ulcer formation.
Fifteen participants who were IL-1 genotype posi-
tive (10 males and five females; mean age: 23.9 –
3.4 years) and 15 participants who were IL-1 geno-
type negative (five males and 10 females; mean
age: 23.9 – 5.3 years) completed the study. Clinical
and demographic information of the patients at base-
line stratified according to IL-1 genotype was ana-
lyzed, and no significant differences were observed
between the two groups (P >0.05) (see Supplemen-
tary Table 1 in online Journal of Periodontology).
Clinical, Microbial, and Biomarker Changes With
Induction of Gingivitis
During the induction phase, a statistically significant
increase in microbial accumulation and subsequent
inflammation was observed in IL-1 genotype–posi-
tive and genotype–negative groups, as demon-
strated by PI, GI, and PBS, although no significant
differences were observed between the two groups
(Fig. 3). Mean PI ( – SE) increased significantly from
0.38 – 0.04 at baseline to 1.41 – 0.04 at day 21 (P
<0.01) (Fig. 3A). Mean GI (– SE) significantly in-
creased from 0.32 – 0.05 at baseline to 1.97 –
0.08 at day 21 (P <0.01) (Fig. 3B). Mean – SE PBS
increased from 0.31 – 0.04 at baseline to 1.34 –
0.05 at day 21 (P <0.01) (Fig. 3C). All clinical pa-
rameters significantly decreased from day 21 to
day 35 (P <0.05).
Total bacterial counts increased significantly from
baseline to day 21 and decreased significantly from
day 21 to day 35 (P <0.05) (Fig. 4A). As the experi-
mental gingivitis phase progressed, the proportion
of orange complex increased, with the most promi-
nent peak at day 21. Mean counts of Prevotella mela-
ninogenica at day 10 were significantly higher in IL-1
genotype–positive participants compared to the IL-1
genotype–negative group (P = 0.001) (Fig. 4B).
IL-1b at day 35 was the salivary biomarker that was
significantly elevated in IL-1 genotype–positive partic-
ipants compared to genotype–negative (P = 0.004)
(Fig. 5). IL-1 genotype–positive participants had con-
sistently higher levels of IL-1a and IL-1b at all time
points (Fig. 5). In IL-1 genotype–positive participants,
salivary IL-1b, IL-10, and TIMP-1 levels increased
during the induction phase, with a decrease of IL-2
and IL-6 levels at resolution. A decrease in the levels
of GCSF, IFN-g, IL-1a, IL-1b, IL-1ra, IL-2, IL-6, IL-8,
IP-10, MCP-1, MMP-2, MMP-8, MMP-9, TIMP-1, and
TIMP-2 was observed in IL-1 genotype–negative par-
ticipants at day 10, after which the biomarkers in-
creased again, although not statistically significantly
(see Supplementary Table 2 in online Journal of Peri-
odontology). Most biomarkers returned to baseline
levels at day 35.
Prediction of Gingivitis Response
Twelve participants belonged to the high responders
group(sixgenotype-positiveandsixgenotype-negative
participants), whereas 18 participants belonged to the
low responders group (nine genotype-positive and nine
genotype-negative participants).
Of the proinflammatory salivary biomarkers, base-
line IL-6 and IL-8 had the highest AUCs of 0.81
and 0.72, respectively. Salivary baseline MMP-1 and
MMP-8 demonstrated the highest AUCs of 0.76 and
0.78, respectively. Subgingival bacterial baseline levels
of Fusobacterium nucleatum polymorphum had the
highest bacterial AUC of 0.75, predicting high versus
low responders, followed by Fusobacterium periodonti-
cum with an AUC of 0.73, Gemella morbillorum with an
AUC of 0.74, and Capnocytophaga ochracea with an
AUC of 0.72.
Figure 6 depicts the AUCs and odds ratios for
various combinations of salivary proinflammatory
cytokines, MMPs, and bacterial pathogens. The com-
posite of IL-6 and MMP-1 generated an AUC of 0.89,
and participants with high levels of both biomarkers
at baseline had 17.0 times the odds (95% confidence
interval, 1.7 to 171.7) of being a high responder than
participants without high levels of both biomarkers
(Fig. 6).
DISCUSSION
The IL-1 family of cytokines is produced primarily by
macrophages and is largely responsible for initiating
the cascade of inflammatory responses.21 Genetic
variations in the IL-1 gene cluster are associated with
a hyperinflammatory state15 that increases suscepti-
bility to periodontal diseases.4,22-26
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The aims of this research are to understand how bio-
markers and periodontal pathogens are modulated
during a bacterially induced gingival inflammation
and to use these findings to identify individuals with
a more exuberant gingivitis response. The presence
of 30 biomarkers associated with host defense, inflam-
mation, tissue destruction, and angiogenesis was ana-
lyzed in saliva. Modulation of these genes and
pathways has been demonstrated in a previous ex-
perimental gingivitis study.27 Our study provides ad-
ditional support to a previous investigation exploring
modulation of genetic pathways in experimental gin-
givitis combining proteomic and microbial genetic
biomarkers to differentiate between various forms of
periodontal diseases14 and extends previous findings
in two areas: 1) we demonstrate the effective use of
saliva to monitor critical gingivitis biomarkers; and
2) we show that a combination of objective baseline
parameters is highly predictive of high responders
to the acute bacterial challenge.
Our study controlled for multiple variables that in-
fluence gingival inflammation. However, a lack of sex
balance between the two genotype groups was ob-
served. Our study was powered to assess overall
biomarker patterns during experimental gingivitis.
However, our study was not powered to detect signif-
icant differences between IL-1 genotypes because of
the relatively small effects of this gene compared to
the dominant effects of bacterial accumulations asso-
ciated with discontinuance of oral hygiene.
The polymorphic loci assessed in our study were
IL-1A + 4845 and IL-1B + 3954. Hence, a patient con-
sidered IL-1 genotype positive had a composite geno-
type that included both SNPs. However, IL-1B gene
transcription is a much more complex process that in-
volves different SNPs of the enhancer-promoter re-
gion of the IL-1B gene. Functional polymorphism of
the IL-1B gene encompasses four functionally active
SNPs in the promoter region: -31, -511, -1464, and
-3737.28 Because these SNPs constantly interact
with each other, examination of the combination of
alleles at different loci that are transmitted together
(i.e., haplotypes) provides a much more compelling
association with clinical phenotypes. Recent stud-
ies found that the combination of various functional
IL-1B haplotypes displayed different levels of biologic
activity and were significantly associated with IL-1b
secretion.28,29 Future studies examining IL-1 geno-
type should be directed at the correlation of these
pairs of haplotypes with various disease pheno-
types, such as elevated levels of salivary biomarkers
and periodontal pathogens. Studies of haplotype
pairs could possibly explain the inconsistency of
the clinical application of testing for IL-1 genotype
and differences among various ethnic popula-
tions.28,30-32
The clinical and microbial responses to cessa-
tion of oral hygiene were consistent with previous
observations.8,33 A decrease in the levels of multiple
biomarkers was observed in IL-1 genotype–negative
participants at day 10, after which the biomarkers
rebounded. Downregulation of biomarkers, such as
IL-1b and IL-8, in the early stages of gingivitis was
reported in previous in vitro34 and experimental gin-
givitis studies.35,36 Some authors proposed that
initially downregulated proinflammatory biomarkers
can suddenly rise and predispose participants to
an exaggerated inflammatory response.36-38
Figure 3.
Longitudinal plots of mean – SE clinical periodontal measures of all
participants from day -21 to day 35. A) PI. B) GI. C) PBS. Statistically
significant increases were found during induction and decreases during
resolution for all parameters (P <0.01).
Host, Genetic, and Biofilm Profile in Experimental Gingivitis Volume 83 • Number 1
84
However, in our study, it appears that this downregu-
lation occurred preferentially on IL-1–negative partic-
ipants, suggesting a protective mechanism against
inflammation. For example, although IL-8 plays a role
in bacterial destruction, a hyperactivity of this cytokine
increases periodontal tissue destruction by increasing
additional neutrophilic infiltration and MMP-8 produc-
tion.39-41 As a result, an initial downregulation of
proinflammatory cytokines may help limit host tissue
degradation. This protective concept is further sup-
ported by a study in which periodontally healthy par-
ticipants displayed significantly higher GCF IL-8
concentration compared to par-
ticipants with gingivitis.39 More-
over, because the IL-1 gene
plays a role
in inflammatory process, func-
tional polymorphism of the
IL-1 gene may be responsible
for the exaggerated inflam-
matory responses observed in
periodontal diseases.4 Future,
higher-powered studies will be
needed to confirm the concept
of biomarker downregulation
during an acute inflammatory
episode.
In our study, bacterial- and
host-derived mediators of peri-
odontal disease consisting of
subgingival species (e.g., F. nu-
cleatum polymorphum), gingi-
val tissue inflammation (e.g.,
IL-8), and extracellular matrix
degradation (e.g., MMP-1 and
MMP-8)wereanalyzed.Thecom-
bination of these three groups
of mediators, reflective of the
course of periodontal diseases,
enhanced the ability to identify
participants with a high gingival
inflammatory profile.
In our study, Fusobacterium
species predispose participants
to a heightened inflammatory
response. These bacterial spe-
cies are one of the most numer-
ous Gram-negative anaerobic
isolates in the gingival sulcus
and are detected in 68% to 90%
of plaque samples from patients
with periodontal diseases.42-45
Fusobacterium species play a
key role in bacterial plaque for-
mation because they coaggre-
gate with most bacteria in the
oral cavity.46 Their ability to identify participants who
are high responders reinforces their role in facilitating
coaggregation between early colonizers in gingivitis
and periodontal pathogens in periodontitis.46 In fact,
Fusobacterium species produce an environment favor-
able for growth of anaerobic pathogens by coaggregat-
ing with facultative organisms that consume the
surrounding oxygen.46 Moreover, C. ochracea as
a secondary colonizer produces succinate that can
be used by Porphyromonas gingivalis to enhance
its growth.47 Therefore, at baseline before the in-
flammatory burden, high responders possess
Figure 4.
A) Pie charts demonstrating proportions of each bacterial complex as defined by Socransky et al.20 in
relation to total DNA from day 0 to day 35. The size of the pies was adjusted to reflect the total DNA probe
count. B) Mean counts (·105) of 40 bacterial species stratified by IL-1 genotype. Blue line delineates
bacterial counts in IL-1 genotype–positive participants. Orange fill represents bacterial counts in IL-1
genotype–negative participants. *P <0.007.
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Figure 5.
Longitudinal plots of mean – SE salivary biomarkers from day 0 to day 35. A) Proinflammatory biomarkers stratified by IL-1 genotype: IL-1a and IL-1b.
Proinflammatory biomarkers of all participants: IL-6 and IL-8. B) MMPs of all participants: MMP-8 and MMP-9. C) Anti-inflammatory of all participants:
IL-10 and TIMP-1. *P <0.007.
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Figure 6.
ROC curves for IL-6 + MMP-1 (A), IL-6 + MMP-8 (B), IL-8 + MMP-1 + F. nucleatum polymorphum (C), IL-8 + MMP-1 + F. periodonticum (D), IL-8 +
MMP-8 + F. nucleatum polymorphum (E), and IL-8 + MMP-8 + F. periodonticum (F). CI-Confidence interval; OR-odds ratio.
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a microbiologic profile that might facilitate coloniza-
tion of periodontal pathogens.
The experimental gingivitis model consists of in-
ducing an acute stage of inflammation to otherwise
healthy patients, creating clinical and immunologic
responses that are different from the naturally occur-
ring chronic development of disease.7,36,48 In experi-
mental gingivitis, participants receive a prophylaxis
and subsequently refrain from all forms of oral hy-
giene for 21 days. In contrast, naturally occurring gin-
givitis patients still maintain some form of oral
hygiene and develop gingivitis over a longer period
of time. In a study by Deinzer et al.,36 plaque accumu-
lation and GCF IL-1b levels were significantly higher
in experimental gingivitis compared to persistent
gingivitis, whereas severity of gingival bleeding and
GCF IL-8 levels were significantly lower. Moreover,
experimental gingivitis lesions are dominated by
a lymphocytic-dominated infiltrate rather than neu-
trophilic.49,50 Despite these differences, the acute in-
flammatory stress induced in experimental gingivitis
has some similarities to active phases of destruction
during chronic periodontitis. As a consequence, data
in this study could reflect the microbiologic profile and
biologic host response during the acute phases of in-
flammation. We also postulate that a subset of partic-
ipants who displayed a biologic profile consistent with
progressive periodontitis may have a cellular infiltrate
or activation state more similar to periodontitis than
gingivitis. For example, participants with high levels
of IL-1b and MMP-8 had 3.47 times the odds of being
a high responder compared to participants with low
levels of these biomarkers (data not shown). Whether
such participants are more prone to progressive peri-
odontitis when challenged remains to be determined.
CONCLUSIONS
Our study demonstrates that patients with high base-
line levels of salivary IL-6 and MMP-1 are at strong risk
of developing a heightened gingival inflammatory re-
sponse compared to individuals displaying low levels
of these biomarkers. Detection of these specific host
and bacterial biomarkers using a practical chairside
salivary test could allow early identification of suscep-
tible patients so that a preventive intervention can be
initiated before irreversible tissue breakdown. Future
studies on large and diverse patient populations will
be needed to validate these findings for application
to the clinical arena.
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